About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.

Colorectal Metastasis Prevention International Trial 2

Clinicaltrials.gov identifier NCT03919461

Recruitment Status Recruiting

First Posted April 18, 2019

Last update posted April 18, 2019

Study Description

Brief summary:

The short perioperative period (days to weeks around surgery) is characterized by stress-inflammatory responses, including catecholamines (CAs, e.g., adrenaline) and prostaglandins (PGs, e.g., prostaglandin-E2) release, and induce deleterious pro-metastatic effects. Animal studies implicated excess perioperative release of CAs and PGs in facilitating cancer progression by affecting the malignant tissue, its local environment, and anti-metastatic immune functions. Congruently, animal studies conducted by the investigators indicate that combined use of the beta-adrenergic blocker, propranolol, and the prostaglandins inhibitor, etodolac - but neither drug separately - efficiently prevented post-operative metastatic development. Two recently conducted clinical trials, conducted by the investigators, in three medical centers in Israel, recruiting breast (n=38) and colorectal (n=34) cancer patients, assessing the safety and short-term efficacy of perioperative propranolol and etodolac treatment. Drugs were well tolerated, without severe adverse events. Importantly, molecular/biological analyses of the excised primary tumor indicated that drug treatment caused promising anti-metastatic transformations, as well as improvements in immune and inflammatory indices. These included (i) decreased tumor cell capacity to migrate, (ii) reduced pro-metastatic capacity of the malignant tissue, and (iii) improvement in immune infiltrating into the tumor (Paper published in Clinical Cancer Research, 2017). Herein, the investigators propose to conduct a double-blind placebo-controlled two-arm Phase II clinical trial in 200 colorectal cancer patients undergoing curative surgery in Israel. A perioperative 20-day drug treatment will be initiated 5 days before surgery. Primary outcomes will include (i) 3-year disease-free-survival (DFS), and 5-year overall survival (OS); and (ii) biological markers in blood samples, and in the excised tumor tissue. Secondary outcomes will include safety indices and psychological measures of depression, anxiety, distress, and fatigue

  • Condition or Disease:Colorectal Neoplasms
  • Intervention/Treatment: Drug: Propranolol and etodolac
    Other: Placebo
  • Phase: Phase 2
Detailed Description


Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 200 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Prevention
  • Official Title: Perioperative Use of a β-adrenergic Blocker, Propranolol, and a COX2 Inhibitor, Etodolac, in Patients Undergoing Resection With Curative Intent for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Survival
  • Actual Study Start Date: February 2019
  • Estimated Primary Completion Date: February 2027
  • Estimated Study Completion Date: February 2027
Arms and interventions
Arm Intervention/treatment
Active Comparator: Propranolol and etodolac
Both study medications will be given orally for an intervention phase of 20 days as follows. Etodolac:400mg PO bid for the entire intervention period, Propranolol (slow release): 20 mg PO b.i.d. for 5 preoperative days; 80 mg PO b.i.d. on the day of surgery; 40 mg PO b.i.d. for the first post-operative week and 20 mg PO b.i.d. for the second post-operative week.
Drug: Propranolol and etodolac
A perioperative combined drug regimen
Placebo Comparator: Placebo
Same schedule as in the active comparator arm
Other: Placebo
Outcome Measures
  • Primary Outcome Measures: 1. 5-year disease-free-survival [ Time Frame: From the date of surgery until malignant disease is identified, assessed up to 60 months post-surgery] ]
    Data regrading post-surgical recurrence will be recorded at 1,3,6,12,18,24,36,48, and 60 following surgery. Primary outcome 1 will be rate of recurrence/disease at 60 months.
  • 2. Biomarkers in extracted tumor tissue samples assessing pro- and anti-metastatic processes [ Time Frame: An average of one year following surgery ]
    Epithelial-to-mesenchymal-transition ( EMT) status and natural-killer cell, macrophage, T-cell, and B-cell infiltration levels into tumor tissue (as assessed by messenger RNA profiling of tissue samples
  • 3. Biomarkers in blood samples assessing pro- and anti-metastatic processes [ Time Frame: An average of one year following surgery ]
    Cytokine levels in blood samples (interleukin-6, interleukin-10, C-reactive protein, interferon-gamma, and vascular endothelial growth factor and additional exploratory analysis of other cytokines)
  • Secondary Outcome Measures: 1. Number of patients with treatment related adverse events [ Time Frame: 30 days following surgery ]
    According to the Clavien-Dindo classification system (7 grades of events depicting the severity of the event)
  • 2. Depression, Anxiety, Global distress [ Time Frame: At baseline and at 30 days post-surgery ]
    Assessed by changes on the brief symptom inventory 18 questionnaire (this questionnaire assess all three scales for depression, anxiety and global distress)
  • 3. Fatigue [ Time Frame: At baseline and at 30 days post-surgery ]
    4 items related to fatigue in the 36 item short-form survey questionnaire.
Eligibility Criteria
  • Ages Eligible for Study: 20 to 80 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Patients planned for surgery for primary resection of colon or rectal cancer with
curative intent. 2. Single colonic or rectal carcinoma, proven by full colonoscopy and
tumor biopsy. 3. No evidence of metastatic disease prior to surgery. Minimal workup would
include abdominal CT with IV contrast (or CT+liver US) and chest XR. 4. ASA score of 1-3 or
ECOG Performance Status of 0 to 1 5. Signed informed consent form 6. Willing and able to
comply with study procedures (physically and mentally) 7. Men and women from age 20 to age


Exclusion Criteria:

1. Patients with metastatic disease, known prior to surgery

2. Patients in whom surgical resection is planned without curative intent

3. Patients with renal failure, measured by creatinine level >1.5

4. Patients with significant heart failure (NYHA functional class 3 or higher)

5. Patients with significant liver failure (known cirrhosis, Bilirubin level>2)

6. Patients currently suffering from asthma or Chronic Obstructive Pulmonary Disease

7. Patients treated pharmacologically for diabetes mellitus (type 1/2),

8. Patients with peripheral vascular disease

9. Patients with known allergy to one or more of the study medications.

10. Patients with known allergy to any medication from the non-steroidal anti-
inflammatory drug group or beta-blockers family

11. Patients treated chronically with any type of a beta-adrenergic blocker or a COX

12. Patients with bradycardia or second or third degree AV block

13. Patients with a history of CVA/TIA

14. Patients with Printzmetal's angina

15. Patients with right sided heart failure owing to pulmonary hypertension

16. Patients with significant diagnosed cardiomegaly

17. Patients with (current) pheochromocytoma

18. Patients with chronic Digoxin treatment

19. Patients with active peptic disease

20. Pregnant women

21. Patients who participate in another interventional study

22. Patients with history or concomitant malignant disease of any type (except for the
current colon/rectal cancer)

23. Patients who were treated with chemotherapy in the last 10 years for any reason
besides neo-adjuvant therapy for rectal cancer within the last six months.

24. Patients who are treated with immunosuppressive medications

25. Patients with Immunodeficiency Disorders, or autoimmune disease treated by
immunosuppressive medications.

26. Patients suffering from sick sinus syndrome

Contacts and Locations

Contact: Oded Zmora, MD +97289779202 ozmora@post.tau.ac.il


HaEmek Medical Center

Rambam Health Care Campus

Rabin Medical Center

Sourasky Medical Center
Tel Aviv

Sheba Medical Center
Tel HaShomer

Asaf Harofeh Medical Center

Sponsors and Collaborators

Assaf-Harofeh Medical Center

Sheba Medical Center

Rabin Medical Center

Tel-Aviv Sourasky Medical Center

Rambam Health Care Campus

HaEmek Medical Center, Israel


Principal Investigator: Oded Zmora, MD Asaf Harofeh Medical Center